Drug Profile

Autologous mesenchymal stem cell therapy - EHL Bio

Alternative Names: ADSTEM injection

Latest Information Update: 03 Feb 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator EHL Bio
Class Mesenchymal stem cell therapies; Stem cell therapies
Mechanism of Action Cell replacements; Stem cell stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

No development reported Atopic dermatitis

Most Recent Events

31 Jan 2026 EHL Bio plans a phase III trial for Atopic dermatitis (Parenteral, Injection) in January 2026 (NCT07377838)
28 Aug 2019 No recent reports of development identified for phase-I development in Atopic-dermatitis in South Korea (IV, Injection)
01 Dec 2017 EHL Bio completes a phase I trial in Atopic dermatitis in South Korea (IV) (NCT02888704)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com